{
    "filename": "0001213900-25-091474_primary_doc.xml",
    "path": "d:\\Files\\Code\\Funkles-SEC\\FunklesScraper\\..\\filings_cache\\0001213900-25-091474_primary_doc.xml",
    "date": "2025-09-25",
    "form": "SCHEDULE 13D",
    "file_type": "SCHEDULE 13D",
    "original_filename": "primary_doc.xml",
    "issuer": "LB Pharmaceuticals Inc",
    "reporting_persons": [
        "Pontifax Management 4 G.P. (2015) Ltd.",
        "Pontifax VI G.P. L.P.",
        "Ran Nussbaum",
        "Tomer Kariv"
    ],
    "cik": "0001691082",
    "label": "Signal activist investment or strategic involvement",
    "summary": "Pontifax Management 4 G.P. (2015) Ltd., Pontifax VI G.P. L.P., Ran Nussbaum, and Tomer Kariv (the \"Reporting Persons\") jointly reported beneficial ownership of 1,411,681 shares of Common Stock of LB Pharmaceuticals Inc., representing 6.3% of the class. This ownership was established on September 12, 2025, through the conversion of previously held Series C Preferred Stock and additional purchases of common stock in the Issuer's initial public offering at $15.00 per share. The Reporting Persons acquired these securities for investment purposes, and Ran Nussbaum serves on the Issuer's Board of Directors.",
    "share %": null
}